Bristol-Myers Squibb Expects Lower FY22 Sales Versus FY21

  • Bristol-Myers Squibb Co BMY has posted Q2 revenues of $11.89 billion, an increase of 2% Y/Y, beating the consensus of $11.45 billion. 
  • Eliquis, Opdivo, Abecma, Opdualag, and Reblozyl drove sales growth, partially offset by the loss of exclusivity products (primarily Revlimid) and foreign exchange impacts.
  • When adjusted for foreign exchange impacts, Q2 revenues increased 5%.
  • Eliquis sales increased 16% to $3.23 billion, Opdivo sales increased 8% to $2.06 billion.
  • Adjusted EPS of $1.93 came ahead of the consensus of $1.82 and 18% higher than the $1.63 posted a year ago.
  • Adjusted gross margin decreased from 79.8% to 78.3%, primarily driven by product mix.
  • Guidance: Bristol Myers reiterated FY22 adjusted EPS guidance of $7.44 - $7.74, compared to the consensus of $7.46.
  • Revenues are expected to be $46 billion (prior view of inline with 2021 of $46.4 billion) compared to the consensus of $46.24 billion.
  • Inline Products & New Product Portfolio is expected to grow in the low-double digits and contribute approximately $36 billion in FY22 (versus the $36.5 billion previously).
  • Price Action: BMY shares are down 1.67% at $72.40 during the premarket session on the last check Wednesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In:
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!